All In MedTech

Device Trial Radar · NCT07804862

Efficacy and Safety of RFA vs MWA for Treatment of Large Benign Thyroid Nodules, RCT

Comparing the Efficacy and Safety of Radiofrequency Ablation Versus Microwave Ablation for the Treatment of Large Benign Thyroid Nodules, a Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Actual

Start

Dec 5, 2023

Primary completion

Oct 1, 2026

Study completion Mar 30, 2027

Sponsor

Lead sponsor
The University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Columbia University
First posted
Sep 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

We conduct a multi-institutional randomized control trial of RFA and MWA for the primary treatment of large, benign nodules. Adult patients \>/=18 years of age who have a solitary thyroid nodule ≥20ml in volume who presents to 1) Columbia University, NY or 2) Queen Mary Hospital, Hong Kong for consultation will be eligible for enrollment in the study. They will need either a) two benign fine needle biopsies, with the most recent biopsy performed within 1 year of enrollment in study or b) one benign fine needle biopsy and low suspicion characteristics on ultrasound. Both functional and non-functional nodules are eligible. Patients will be randomly assigned to either treatment arm a) RFA or treatment arm b) MWA according to a pre-generated block randomization list.

Conditions

  • Ablation Techniques, RFA
  • Ablation Treatment
  • Benign Thyroid Nodules
  • Local Anaesthesia

Interventions

  • Radiofrequency ablation aloneDevice

    Ultrasound-guided thermal ablation will be performed using STARmed internally cooled RFA electrodes (18 gauge) powered by the VIVA RF generator in accordance with the trans-isthmic 'moving shot' technique.

  • Microwave ablationDevice

    Ultrasound-guided thermal ablation will be performed using ECO Medical internally cooled MWA antennas (16 or 17 gauge) powered by the ECO Medical generator in accordance with the trans-isthmic 'moving shot' technique.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Volume reduction rate (VRR) of thyroid nodule at 6 months (%)Time frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Queen Mary Hospital

    Hong Kong, Hong Kong

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.